Literature DB >> 7620958

Rifampicin impregnated Dacron grafts: no development of rifampicin resistance in an animal model.

F Sardelic1, P Y Ao, J P Fletcher.   

Abstract

AIM: Rifampicin impregnated Dacron grafts have been shown to be effective at preventing vascular graft infection in different animal models. The development of resistance to rifampicin would be a major drawback to the widespread use of such a graft. We aimed to determine how readily this would occur by using a sheep animal model.
METHODS: Under general anaesthetic a 2cm long, 5mm diameter Dacron interposition graft inpregnated with 1.2 mg/ml rifampicin was placed in the left carotid artery. An extreme challenge of methicillin resistant Staphylococcus aureus (MRSA) using an inoculum of 10(9) colony forming units was placed directly onto the graft. The grafts were harvested at 3 weeks and cultures of the graft and tissues were taken. The presence or absence of any abscess formation, anastomotic disruption and graft thrombosis was noted. Any positive growths were identified and if found to be the same as the inoculum, the bacteria were used as the inoculum for another sheep. This was repeated once more. Thus we started with three sheep initially and used a total of nine sheep.
RESULTS: There were no deaths. All grafts were infected with the same MRSA strain, confirmed on phage typing. There were three abscess and one anastomotic disruption. Seven of the grafts were occluded. The minimal inhibitory concentration (MIC) of the infecting inoculum and the bacteria retrieved were determined using the agar dilutional method. The MIC for the three initial inocula was < 0.007 mg/l. All subsequent strains isolated had an MIC of < 0.015 mg/l. This was a difference of one dilution and not significant.
CONCLUSION: There was no development of rifampicin resistance using this animal model.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620958     DOI: 10.1016/s1078-5884(05)80137-6

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  4 in total

1.  Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection.

Authors:  A Giacometti; O Cirioni; R Ghiselli; L Goffi; C Viticchi; F Mocchegiani; A Riva; F Orlando; V Saba; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Polycationic peptides as prophylactic agents against methicillin-susceptible or methicillin-resistant Staphylococcus epidermidis vascular graft infection.

Authors:  A Giacometti; O Cirioni; R Ghiselli; L Goffi; F Mocchegiani; A Riva; G Scalise; V Saba
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

3.  Efficacy of quinupristin-dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides.

Authors:  Andrea Giacometti; Oscar Cirioni; Roberto Ghiselli; Fiorenza Orlando; Federico Mocchegiani; Alessandra Riva; Maria Simona Del Prete; Vittorio Saba; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

Review 4.  The potential for developing new antimicrobial resistance from the use of medical devices containing chlorhexidine, minocycline, rifampicin and their combinations: a systematic review.

Authors:  Ruth A Reitzel; Joel Rosenblatt; Bahgat Z Gerges; Andrew Jarjour; Ana Fernández-Cruz; Issam I Raad
Journal:  JAC Antimicrob Resist       Date:  2020-02-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.